“Cambridge, Massachusetts-based next-generation sequencing firm Foundation Medicine – now owned by Swiss drugmaker Roche – said Tuesday that it had signed a contract with the Department of Veterans Affairs’ National Precision Oncology Program to provide comprehensive genomic profiling for veterans with advanced cancers. The contract will cover all the company’s tests, including FoundationOne CDx, FoundationOne Liquid and FoundationOne Heme.”
“The company, which appointed Cindy Perettie as its CEO last month, launched the liquid biopsy test in September…”
“One potential opportunity that the partnership affords if for medical research. Most of the VA hospitals, Civik said, are either attached or close to teaching institutions where large clinical trials take place. Consequently, in addition to an interest in using its NGS tests to match patients to targeted therapies, there is also a strong interest in…” Read the full article here.
Source: Foundation Medicine signs $111M contract with Department of Veterans Affairs – By Alaric DeArment, February 5, 2019. MedCityNews.
